학술논문
EMR 20006-012: A phase II randomized double-blind placebo controlled trial comparing the combination of pimasertib (MEK inhibitor) with SAR245409 (PI3K inhibitor) to pimasertib alone in patients with previously treated unresectable borderline or low grade ovarian cancer
Document Type
Article
Author
Source
In Gynecologic Oncology February 2020 156(2):301-307
Subject
Language
ISSN
0090-8258